By Alicia Ault
NEW YORK (Reuters Health) – Atrix Laboratories Inc. said on Thursday that it had received US Food and Drug Administration (FDA) approval for its Eligard 7.5 mg prostate cancer drug.
Formerly known as Leuprogel One-Month Depot, Eligard is injected just under the skin, usually above the hip. There, it turns into a biodegradable implant, and the active ingredient, leuprolide acetate, is gradually released. The 7.5 mg dose is delivered over a one-month period.
Atrix CEO David Bethune said in a conference call Thursday that in clinical trials, Eligard substantially reduced testosterone levels in men with hormone-responsive prostate cancer.
Ramon Perez, an Atrix investigator at the Urology Health Center in New Port Ritchie, Florida, believes that urologists are looking forward to a new technology. "Eligard gets dissolved in a predictable fashion for a predictable amount of time, so there is no guessing here," he said, adding that would make patients feel better and help repress tumors.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!